Therapeutic potential of chemokine receptor antagonists for liver disease. - Wikidata - awgldk - TriplyDB

Therapeutic potential of chemokine receptor antagonists for liver disease.

Therapeutic potential of chemokine receptor antagonists for liver disease.

http://www.wikidata.org/entity/Q37960533

about

Met-CCL5 modifies monocyte subpopulations during liver fibrosis regression.IL-17A and IL-25: therapeutic targets for allergic and exacerbated asthmatic disease.

P2860

Q39248425-82630E58-5C26-46AC-B289-8F4459BCFCE7 Q39619506-7BBE8B47-F38F-4B36-95DB-9A7D6E0DC27F

P2860

Therapeutic potential of chemokine receptor antagonists for liver disease.

http://www.wikidata.org/entity/Q37960533

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Therapeutic potential of chemokine receptor antagonists for liver disease.

@en

Therapeutic potential of chemokine receptor antagonists for liver disease.

@nl

type

label

Therapeutic potential of chemokine receptor antagonists for liver disease.

@en

Therapeutic potential of chemokine receptor antagonists for liver disease.

@nl

prefLabel

Therapeutic potential of chemokine receptor antagonists for liver disease.

@en

Therapeutic potential of chemokine receptor antagonists for liver disease.

@nl

P1433

Q37960533-4FDF82C0-184A-4A28-8582-DF74300A6893

P1476

Q37960533-56B5818F-320D-4DCD-9C75-144D489FFC75

P2093

Q37960533-0D13591B-99BF-4333-8B5A-FC7872DAFAB8

Q37960533-5D4D49F6-A2F9-496D-BD94-925860F3CAF0

Q37960533-660B4E7C-D34C-4938-B6FB-DEE07B7FA3D4

P2860

Q37960533-06DD997F-83E6-4588-924C-E17F3961DB44

Q37960533-0B80F267-2A92-42B1-9A03-B633FD95A0F1

Q37960533-139B5E75-DF71-4829-AFB7-345DA0EC7A5F

Q37960533-13C5851D-14C0-481C-B635-8BEC2102B4A6

Q37960533-16569FAF-7CD1-4675-9833-08E479E08D68

Q37960533-17C4A0CE-E6AE-4136-84C3-E6398711E778

Q37960533-1899BC22-5AB3-4D82-98A9-A7AD7D37072D

Q37960533-19B58936-A441-467F-A441-68C815860FAF

Q37960533-1AE20E97-2AF1-46F5-99CA-ED9BF0CC0F91

Q37960533-1E186644-850D-4513-9E60-E5C9AAF77254

P304

Q37960533-733472E2-E6AB-42D9-B6B5-18B3E3FBF02C

P31

Q37960533-6A6CA0AC-2442-4996-8B43-3BD9290ACD53

P356

Q37960533-641E0B46-3EDA-4BFC-87C4-93A3280422C9

P407

Q37960533-0582219E-6C1F-4A83-8D3B-AE1C26C78693

P433

Q37960533-4D53112B-C745-4963-92BB-A5C781591D30

P478

Q37960533-9C27CFC4-8A93-49B0-8A91-1ACA40CAD4DE

P577

Q37960533-BD43F01F-411F-466A-90C7-837742C73E1B

P698

Q37960533-8B426541-4730-40F2-89B5-15ED67B024CF

P356

P1433

Expert Review of Clinical Pharmacology

P1476

Therapeutic potential of chemokine receptor antagonists for liver disease.

@en

P2093

Hacer Sahin

http://www.w3.org/2001/XMLSchema#string

Hermann E Wasmuth

http://www.w3.org/2001/XMLSchema#string

Marie-Luise Berres

http://www.w3.org/2001/XMLSchema#string

P2860

An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4

CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature

CXCR7 functions as a scavenger for CXCL12 and CXCL11

The CCR5- 32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source

Association of pretreatment serum interferon inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C

Fine-tuning leukocyte responses: towards a chemokine 'interactome'

Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection

MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment

ELR+-CXC chemokines and their receptors in early metanephric development

Blood monocytes consist of two principal subsets with distinct migratory properties

P304

503-513

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ECP.11.24

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22114859

http://www.w3.org/2001/XMLSchema#string